CHECKPOINT

作品数：720被引量：1395H指数：15
导出分析报告
相关领域：医药卫生自动化与计算机技术更多>>
相关作者：段红刘穆进张彩田志刚景年财更多>>
相关机构：上海大学华中科技大学国防科学技术大学CheckPoint软件技术有限公司更多>>
相关期刊：更多>>
相关基金：国家自然科学基金中国博士后科学基金广东省自然科学基金国家重点基础研究发展计划更多>>
-
在结果中检索

检索结果分析

结果分析中...
选择条件：
  • 期刊=Frontiers of Medicinex
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Intracellular checkpoints for NK cell cancer immunotherapy
《Frontiers of Medicine》2024年第5期763-777,共15页Yingying Huang Zhigang Tian Jiacheng Bi 
supported by the National Key R&D Program of China(No.2020YFA0710802 to Jiacheng Bi);Guangdong Basic and Applied Basic Research Foundation(No.2021A1515110174 to Yingying Huang);the National Natural Science Foundation of China(No.82071768 to Jiacheng Bi).
Natural killer(NK)cells are key innate immune lymphocytes,which play important roles against tumors.However,tumor-infiltrating NK cells are always hypofunctional/exhaustive.On the one hand,this state is contributed by...
关键词：genomic editing NK cell exhaustion immune checkpoint inhibitory molecules immune tolerance 
EBV-associated lymphoproliferative disease post-CAR-T cell therapy
《Frontiers of Medicine》2024年第2期394-398,共5页Shiyuan Zhang Xiaoxi Zhou Shangkun Zhang Na Wang Tongcun Zhang Donghua Zhang Qilin Ao Yang Cao Liang Huang 
supported by the funding from the National Natural Science Foundation of China(No.82070211 to Dr.Liang Huang);the National Key R&D Program of China(No.2022YFC2502604 to Dr.Liang Huang).
Epstein–Barr virus(EBV)-associated lymphoproliferative diseases(EBV-LPDs)are common complications that occur after solid organ transplantation or allogeneic hematopoietic stem-cell transplantation(HSCT).However,their...
关键词：EBV-associated lymphoproliferative disease chimeric antigen receptor T-cell autologous stem cell transplantation immune checkpoint inhibitor 
Immunometabolism:a new dimension in immunotherapy resistance被引量：1
《Frontiers of Medicine》2023年第4期585-616,共32页Chaoyue Xiao Wei Xiong Yiting Xu Ji’an Zou Yue Zeng Junqi Liu Yurong Peng Chunhong Hu Fang Wu 
supported by research grants from the National Natural Science Foundation of China(No.82272806);the Natural Science Foundation of Hunan Province for Excellent Young Scholars(No.2021JJ20088);Frontier Cross Research Project of Central South University(2023QYJC039)to Fang Wu.
Immune checkpoint inhibitors(ICIs)have demonstrated unparalleled clinical responses and revolutionized the paradigm of tumor treatment,while substantial patients remain unresponsive or develop resistance to ICIs as a ...
关键词：immune cell immunometabolism metabolic reprogramming IMMUNOTHERAPY resistance tumor microenvironment immune checkpoint inhibitor 
Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions被引量：5
《Frontiers of Medicine》2023年第1期18-42,共25页Jia Zhong Hua Bai Zhijie Wang Jianchun Duan Wei Zhuang Di Wang Rui Wan Jiachen Xu Kailun Fei Zixiao Ma Xue Zhang Jie Wang 
Beijing Natural Science Foundation(No.7222144);National Key Research and Development Project(No.2019YFC1315700);CAMS Key Laboratory of Translational Research on Lung Cancer(No.2018PT31035).
With the improved understanding of driver mutations in non-small cell lung cancer (NSCLC), expanding the targeted therapeutic options improved the survival and safety. However, responses to these agents are commonly t...
关键词：non-small cell lung cancer driver mutations treatment strategy resistant mechanism immune-checkpoint inhibitors 
Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors被引量：2
《Frontiers of Medicine》2022年第5期773-783,共11页Kaili Yang Jiarui Li Lin Zhao Zhao Sun Chunmei Bai 
This work was supported by the National Natural Science Foundation of China(No.61435001);CAMS Innovation Fund for Medical Sciences(Nos.2017-I2M-4-003 and 2016-I2M-1-001).
The total number of cancer patients who are eligible for and will benefit from immune checkpoint inhibitors(ICIs)in China has not been quantified.This cross-sectional study was conducted to estimate the number of Chin...
关键词：BENEFIT China ELIGIBILITY immune checkpoint inhibitor public health 
Innate immune checkpoint Siglec10 in cancers:mining of comprehensive omics data and validation in patient samples被引量：2
《Frontiers of Medicine》2022年第4期596-609,共14页Chen Zhang Jiandong Zhang Fan Liang Han Guo Sanhui Gao Fuying Yang Hua Guo Guizhen Wang Wei Wang Guangbiao Zhou 
supported by the National Key Research and Development Program of China(No.2020YFA0803300);the CAMS Initiative of Innovative Medicine(2021-1-I2M-014);the CAMS Innovation Fund for Medical Sciences(CIFMS)(Nos.2021-RC310-003 and 2020-RC310-002);the Key Project of the National Natural Science Foundation of China(No.81830093);the National Natural Science Funds for Distinguished Young Scholar(No.81425025);the National Natural Science Foundation of China(Nos.81672765,81802796,and 82073092).
Sialic acid binding Ig-like lectin 10(Siglec10)is a member of innate immune checkpoints that inhibits the activation of immune cells through the interaction with its ligand CD24 on tumor cells.Here,by analyzing public...
关键词：innate immune checkpoint Siglec10 kidney renal clear cell carcinoma 
Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy被引量：1
《Frontiers of Medicine》2022年第3期307-321,共15页Yingying Li Shiyuan Wang Mengmeng Lin Chunying Hou Chunyu Li Guohui Li 
supported by Bijing Hope Run Special Fund of Cancer Foundation of China(No.LC2020L03)and Bejig Municipal Science&Technology Commission(No.Z1811000-01618003).
The discovery of immune checkpoint inhibitors,such as PD-1/PD-L1 and CTLA-4,has played an important role in the development of cancer immunotherapy.However,immune-related adverse events often occur because of the enha...
关键词：tumor immunotherapy immune checkpoint inhibitor ANTIBIOTICS gut microbiota drug–drug interaction 
Advances on immune-related adverse events associated with immune checkpoint inhibitors被引量：11
《Frontiers of Medicine》2021年第1期33-42,共10页Yong Fan Yan Geng Lin Shen Zhuoli Zhang 
supported by the Beijing Natural Science Foundation(No.7184251);National Natural Science Foundation of China(Nos.91442120 and 81771740).
Immunotherapy has recently led to a paradigm shift in cancer therapy,in which immune checkpoint inhibitors(ICIs)are the most successful agents approved for multiple advanced malignancies.However,given the nature of th...
关键词：cancer IMMUNOTHERAPY immune checkpoint inhibitors immune-related adverse events review 
PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives被引量：18
《Frontiers of Medicine》2019年第4期438-450,共13页Yumeng Wang Guiling Li 
This work was supported by the National Natural Science Foundation of China (No. 81373867).
Cervical cancer (CC) is the fourth most commonly diagnosed female malignancy and a leading cause of cancer-related mortality worldwide, especially in developing countries. Despite the use of advanced screening and pre...
关键词：PD-1 PD-L1 immune CHECKPOINT BLOCKADE ANTIBODY immunotherapy CERVICAL cancer 
Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases被引量：1
《Frontiers of Medicine》2019年第1期24-31,共8页Zhen Xiang Yingyan Yu 
the National Key R&D Program of China (Nos.2016YFC1303200 and 2017YFC0908300);the National Natural Science Foundation of China (Nos.81772505 and 81372644);the Shanghai Science and Technology Committee (No.18411953100);the Cross-Institute Research Fund of Shanghai Jiao Tong University (Nos.YG2017ZD01 and YG2015MS62);the Innovation Foundation of Translational Medicine of Shanghai Jiao Tong University School of Medicine (Nos.15ZH4001, TM201617, and TM201702);the Technology Transfer Project of the Science and Technology Department of Shanghai Jiao Tong University School of Medicine.
Immune checkpoint inhibitors are a promising strategy in the treatment of cancer, especially advanced types. However, not all patients are responsive to immune checkpoint inhibitors. The response rate depends on the i...
关键词：IMMUNE CHECKPOINT BLOCKADE sensitivity resistance data mining 
全选清除导出
共2页<12>
检索报告 对象比较 聚类工具 使用帮助 返回顶部